Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Post by loonietuneson Aug 29, 2013 11:31pm
170 Views
Post# 21708390

Corporate yr. end had to be done today.

Corporate yr. end had to be done today.Long weekend means no one will be in the office much past lunch!  To the point of the strip ratio while high, not the be all at this stage of the exercise.  We're at 1st base in my best guess on this play home plate is a long ways away from here, PEA,PFS, we may never get there, but the time for takeout has passed with a premium attached!  We were never on Heclas radar screen they're too busy trying to figure the mess they've bought themselves into ARZ wasn't a huge prize and in my opinion they overpaid.  Time will tell.

I'll just tell a short story about RDU which looked very much like we did this time last yr. Simon and his team, in my mind were on the verge of cash flowing from the JV partner and a small scale operation or being taken out by BTO which I own only because they took out Central Sun which I owned by takeover.  Now Radius has $20 mil in BTO shares to spend plus JV with FVI still in the hopper plus all the other ground.  RDU and NOX share 2 things lots of potential and guys who have played this game far better than I ever will.  When SH made their transition to the new format I suggested shareholders visit kitco to watch a video pub crawl at the end of PDAC because looking at the people will tell you way more than mere numbers.  I review it periodically to see if anything has changed.  What they said in March is still true now.  With only a 16 mil mkt cap I still expect these boys to do a raise shortly while dillutive in the short term the long term benifits outweigh the markets disdain.  What I'd really like to see is a shareholders rights offering with a discount to the 20 day + maybe a 1/2 warrant-it'd take the tax loss sellers out of the game as they're about to be ready to go in Oct.
Sorry bout that wasn't that short was it, but it's only 1 one many prospects we have here going forward


<< Previous
Bullboard Posts
Next >>